Transgene Biotek Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023
For the full year, sales was INR 0.550847 million compared to INR 0.866949 million a year ago. Revenue was INR 2.3 million compared to INR 2.99 million a year ago. Net loss was INR 60.09 million compared to INR 104.02 million a year ago. Basic loss per share from continuing operations was INR 0.79 compared to INR 1.37 a year ago. Diluted loss per share from continuing operations was INR 0.79 compared to INR 1.37 a year ago.